GeneralConnection.com ➔ Dictionary
Dictionary Search

factor xi

Synonyms

Noun

1. plasma thromboplastin antecedent

2. factor XI, coagulation factor, clotting factor

Usage
Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism - Nature
Factor XI Inhibitors: The Future of Anticoagulation - Pharmacy Times
Association of Coagulation Factor XI Level With Cardiovascular Events and Cardiac Function in Community-Dwelling Adults: From ARIC and CHS - American Heart Association Journals
Factor XI inhibitors are the novel promising anticoagulants in the treatment of age related thrombotic disease - Frontiers
Low Bleeding Risk With Abelacimab in AF Patients Undergoing Invasive Procedures - TCTMD.com
Anti-Factor XI Anticoagulants: Breakthrough or Bust? - Medscape
New Factor XI inhibitor shows superior safety in treating atrial fibrillation - News-Medical
Recombinant Activated Factor VIIa Combined With Tranexamic Acid Control Haemostasis in Patients With Severe Factor XI Deficiency Undergoing Urological Procedures - Wiley Online Library
Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders - Business Wire
Factor XI Inhibitors Are a Safer Option for Stroke Prevention | ACC 2025 - Managed Healthcare Executive
Novartis pays $925M to reel in a startup it helped launch - BioPharma Dive
Asundexian versus Apixaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk - GlobeNewswire
Novel Anticoagulant Flops for Staving Off Graft Thrombosis in Dialysis Patients - MedPage Today
Regeneron anticoagulant bests enoxaparin, matches Eliquis in phase 2 trial - Fierce Biotech
NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear - TCTMD.com
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patient - GlobeNewswire
Regeneron says study data support big bet on new blood thinners - BioPharma Dive
Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition - Business Wire
CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies - GlobeNewswire
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban - GlobeNewswire
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation - The New England Journal of Medicine
Abelacimab: the next frontier in safer anticoagulation therapy - Drug Target Review
Novartis inks $925M Anthos takeover to buy back phase 3 clot-busting candidate - Fierce Biotech
New Data Highlights Abelacimab’s Safety Advantage in Atrial Fibrillation - Pharmacy Times
Injectable Anticoagulant Substantially Cuts Bleeding Risk in Afib - MedPage Today
Factor Xa and Factor XI Inhibitors: What Lies Ahead for Anticoagulants - The Cardiology Advisor
The effect of coagulation traits on the risk of retinal vein occlusion: a mendelian randomization study - Nature
Novartis buys Blackstone's Anthos for up to $3.1 billion - Reuters
Anthos spells out benefits of abelacimab in quest for safer blood thinners - FirstWord Pharma
Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation - Business Wire
Anticoagulants for atrial fibrillation: from warfarin and DOACs to the promise of factor XI inhibitors - Frontiers
Asundexian for AF? More Details on the Sinking of OCEANIC-AF - TCTMD.com
Study Demonstrates Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age, Bleeding Risk - Diagnostic and Interventional Cardiology
Factors XI and XII as Targets for New Anticoagulants - Frontiers
Stars align for CRISPR Tx, Sirius as pair pens siRNA collab with a focus on thrombotic disease - Fierce Biotech
Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab - AJMC
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Blackstone
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio - geneonline.com
Jan 24, 2025 This Week in Cardiology Podcast - Medscape
Novartis nets potential first-in-class medicine in new cardiovascular acquisition - European Pharmaceutical Review
New class of anticoagulant found to ‘overwhelmingly’ reduce bleeding events in patients with atrial fibrillation - The Pharmaceutical Journal
Effects of storage time and temperature on coagulation factor and natural anticoagulant activities in healthy individuals - Nature
Abstract 4143980: Bleeding with the FXI Inhibitor Abelacimab compared with Rivaroxaban in Patients on Antiplatelet therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial - American Heart Association Journals
Factor XI, a potential target for anticoagulation therapy for venous thromboembolism - Frontiers
Factor XI Inhibitors for Prevention and Treatment of Venous Thromboembolism: A Review on the Rationale and Update on Current Evidence - Frontiers
Clinical Trial Opportunity for Afib Patients Who Don’t Take an Anticoagulant - National Blood Clot Alliance
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition - BioSpace
Study reveals abelacimab’s potential to improve anticoagulation safety for AFib patients - News-Medical
Raloxifene and estradiol have contrasting effects on hemostasis and... - researchgate.net
Pharmacology and Clinical Development of Factor XI Inhibitors | Circulation - American Heart Association Journals
Abelacimab Cuts AF Bleeding Risk Across Ages with Christian Ruff, MD, MPH - HCPLive
Novartis Welcomes Abelacimab Back Into The Fold With Anthos Acquisition - insights.citeline.com
Christian T. Ruff, MD, MPH: Abelacimab Limits Bleeding Events in AZALEA–TIMI 71 Trial - HCPLive
Regeneron advances anticoagulant antibody pair to late-stage testing - FirstWord Pharma
Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure - Science | AAAS
New data reveal how Bayer's asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes - Fierce Biotech
Novartis buys back Anthos Therapeutics for up to $3.1B - Medical Marketing and Media
Factor XI Deficiency: Practice Essentials, Background, Pathophysiology - Medscape
Biologic demonstrates “tremendous” potential advance in atrial fibrillation - European Pharmaceutical Review
Siddharth Patel, MD, MPH: Abelacimab Could Help Reduce Procedure-Related Bleeding - HCPLive
Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos - Endpoints News
Milvexian: An Oral, Bioavailable Factor XIa Inhibitor - springermedizin.de
What Is the Future of Factor XI Inhibitors? - American Heart Association Journals
Coagulation cascade and Factor XI inhibitors. FXI(a), factor XI(a);... - researchgate.net
Q&A: Failure of OCEANIC-AF trial may not dampen future of factor XI/XIa inhibitors - Healio
Factor XI Inhibitors: The Promise of a Truly Safe Anticoagulant? - Medscape
Abelacimab, a “Game Changer” for High-Risk Patients With AFib: Dr Ruff and Dr Bloomfield Elaborate on Latest Data From AZALEA-TIMI 71 Trial - AJMC
Anthos' detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer's failed? - Endpoints News
New Therapeutic Targets for the Prevention and Treatment of Venous Thromboembolism With a Focus on Factor XI Inhibitors - American Heart Association Journals
FIGURE 1: Rotational thromboelastometry (ROTEM) traces of the clinical... - researchgate.net
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial - Nature
Stopping abelacimab may not be necessary before invasive procedures - Healio
ISTH announces launch of new global education initiative in factor XI/XIa inhibition - PR Newswire
‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar - Endpoints News
Figure 1 Mechanism of action of factor XI(a) inhibitors. Adapted... - researchgate.net
CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer - Endpoints News
New anti-clotting medication reduces bleeding among people with atrial fibrillation - www.heart.org
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Anthos Therapeutics - BioSpace
Genetically Determined FXI (Factor XI) Levels and Risk of Stroke - American Heart Association Journals
Abelacimab for Prevention of Venous Thromboembolism - The New England Journal of Medicine
Liver-derived factor XI protects against HFpEF - Nature
-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: Loss of inhibition by clipped β - PNAS
Effect of the Factor XIa Inhibitor Asundexian According to Baseline Infarct Pattern and on MRI Covert Infarct Outcomes - American Heart Association Journals
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis - The New England Journal of Medicine
Factor XI inhibitor for AF drastically reduces bleeding vs. rivaroxaban in phase 2 trial - Healio
Liver-heart cross-talk mediated by coagulation factor XI protects against heart failure - Science | AAAS
A Novel Antithrombotic Mechanism Mediated by the Receptors of the Kallikrein/Kinin and Renin–Angiotensin Systems - Frontiers
Feedback activation of factor XI by thrombin does not occur in plasma - PNAS
Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial - American Heart Association Journals
Factor XI inhibitors in patients with cardiovascular disease and a high risk of bleeding: a cautionary tale - Nature
AB023, A Novel Antibody That Binds Factor XI and Blocks Its Activation by Factor XIIa - American Heart Association Journals
Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma - PNAS
Endothelial PAI-1 (Plasminogen Activator Inhibitor-1) Blocks the Intrinsic Pathway of Coagulation, Inducing the Clearance and Degradation of FXIa (Activated Factor XI) - American Heart Association Journals
Anthos Therapeutics' Novel Dual-Acting Factor XI/XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation - Business Wire
Discovery of Heparin Mimetic, Potent, and Selective Inhibitors of Human Clotting Factor XIIIa - ACS Publications
OCEANIC-AF study stopped early due to lack of efficacy - Bayer
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI - PNAS
Merging Biocatalysis, Flow, and Surfactant Chemistry: Innovative Synthesis of an FXI (Factor XI) Inhibitor - ACS Publications
Foreign Language Equivalents
Foreign Language Equivalents of 'factor xi'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
ffactor xi,   factor xu,   dactor xi,   facttor xi,   facctor xi,   factor ix,   facto xi,   facor xi,   facror xi,   factro xi,   fctor xi,   fatcor xi,   fsctor xi,   factor ci,   facyor xi,   facto rxi,   facotr xi,   fator xi,   factor i,   factorr xi,   factir xi,   factorx i,   afctor xi,   factot xi,   factorxi,   factoor xi,   faactor xi,   factor xii,   factor zi,   factpr xi,   facter xi,   favtor xi,   gactor xi,   factor xxi,   factor xi,   factoe xi,   faxtor xi,   fcator xi,   factr xi,   factor xo,   actor xi,   factor x
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z